The cell exhaustion marker TIGIT was more abundant on lymphocytes of glioblastoma patients in comparison to HC and RRMS patients, on CD4+ lymphocytes of glioblastoma patients compared to HC, and on NK cells of glioblastoma in relation to RRMS patients. This evidence concerns the gene CD4 and glioblastoma.